Evidence map›Paper›PMID 27483322›Full record

ArticleCancers2016

Human Papillomavirus Genotype Distribution in Invasive Cervical Cancer in Pakistan.

Asif Loya, Beatriz Serrano, Farah Rasheed, Sara Tous, Mariam Hassan, Omar Clavero, Muhammad Raza, Silvia De Sanjosé, F Xavier Bosch, Laia Alemany

Abstract read
In one paragraph

Article in Cancers, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Asif LoyaDepartment of Pathology, Shaukat Khanum Memorial Cancer Hospital and Research Centre Lahore, Punjab 54000, Pakistan. asifloya@skm.org.pk.
Beatriz SerranoUnit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO)-IDIBELL, L'Hospitalet de Llobregat, Gran Via de l'Hospitalet, 199-203, 08908 L'Hospitalet de Llobregat, Barcelona, Spain. crc3@skm.org.pk.
Farah RasheedClinical Research Office, Shaukat Khanum Memorial Cancer Hospital and Research Centre Lahore, Punjab 54000, Pakistan. bscarro@iconcologia.net.
Sara TousUnit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO)-IDIBELL, L'Hospitalet de Llobregat, Gran Via de l'Hospitalet, 199-203, 08908 L'Hospitalet de Llobregat, Barcelona, Spain. crc@skm.org.pk.
Mariam HassanClinical Research Office, Shaukat Khanum Memorial Cancer Hospital and Research Centre Lahore, Punjab 54000, Pakistan. stous@iconcologia.net.
Omar ClaveroUnit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO)-IDIBELL, L'Hospitalet de Llobregat, Gran Via de l'Hospitalet, 199-203, 08908 L'Hospitalet de Llobregat, Barcelona, Spain.
Muhammad RazaDepartment of Pathology, Shaukat Khanum Memorial Cancer Hospital and Research Centre Lahore, Punjab 54000, Pakistan. drrazamuhammadi@gmail.com.
Silvia De SanjoséUnit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO)-IDIBELL, L'Hospitalet de Llobregat, Gran Via de l'Hospitalet, 199-203, 08908 L'Hospitalet de Llobregat, Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP). Madrid, Spain. s.sanjose@iconcologia.net.
F Xavier BoschUnit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO)-IDIBELL, L'Hospitalet de Llobregat, Gran Via de l'Hospitalet, 199-203, 08908 L'Hospitalet de Llobregat, Barcelona, Spain.
Laia AlemanyUnit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO)-IDIBELL, L'Hospitalet de Llobregat, Gran Via de l'Hospitalet, 199-203, 08908 L'Hospitalet de Llobregat, Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP). Madrid, Spain. lalemany@iconcologia.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Few studies have assessed the burden of human papillomavirus (HPV) infection in Pakistan. We aim to provide specific information on HPV-type distribution in invasive cervical cancer (ICC) in the country. A total of 280 formalin-fixed paraffin-embedded tissue blocks were consecutively selected from Shaukat Khanum Memorial Cancer Hospital and Research Centre (Lahore, Pakistan). HPV-DNA was detected by SPF10 broad-spectrum PCR followed by DNA enzyme immunoassay and genotyping by LiPA25. HPV-DNA prevalence was 87.5% (95%CI: 83.0-91.1), with 96.1% of cases histologically classified as squamous cell carcinoma. Most of the HPV-DNA positive cases presented single infections (95.9%). HPV16 was the most common type followed by HPV18 and 45. Among HPV-DNA positive, a significantly higher contribution of HPV16/18 was detected in Pakistan (78.4%; 72.7-83.3), compared to Asia (71.6%; 69.9-73.4) and worldwide (70.8%; 69.9-71.8) and a lower contribution of HPVs31/33/45/52/58 (11.1%; 7.9-15.7 vs. 19.8%; 18.3-21.3 and 18.5%; 17.7-19.3). HPV18 or HPV45 positive ICC cases were significantly younger than cases infected by HPV16 (mean age: 43.3, 44.4, 50.5 years, respectively). A routine cervical cancer screening and HPV vaccination program does not yet exist in Pakistan; however, the country could benefit from national integrated efforts for cervical cancer prevention and control. Calculated estimations based on our results show that current HPV vaccine could potentially prevent new ICC cases.

Indexed as

cervical cancerepidemiologygenotypehuman papillomavirushuman papillomavirus vaccinesPakistan

Identifiers

PMID27483322
PMCPMC4999781

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.